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Abstract
OBJECTIVE: To study the preventative effects of
Dongchongxiacao (Cordyceps) on contrast-induced
nephropathy (CIN) in patients with stable angina
pectoris (SAP).
METHODS: One-hundred and three SAP inpatients
were divided randomly into two groups: basic treat-
ment (n=51) and Dongchongxiacao (Cordyceps)
treatment (n=52); corbrin capsules (3 g; t.d.s.) were
used 3 days before angioplasty and 3 days after an-
gioplasty). Serum creatinine (Scr) was assessed at
the time of hospital admission and 1, 2, and 3 days
after angioplasty. Values of kidney injury mole-
cule-1 (KIM-1), neutrophil gelatinase-associated li-
pocalin (NGAL) and interleukin (IL) 18 in the kidney
were detected before angioplasty and 1 day after
angioplasty in the patients of both groups. The
prevalence of CIN between the two groups was
then compared.
RESULTS: CIN occurred in 9 of 103 patients (8.74%).
The prevalence of CIN in the Dongchongxiacao
(Cordyceps) treatment group was lower than that of
the basic treatment group (5.77% vs 11.76% ) but
the difference was not significant (P>0.05). The
post-procedure mean peak of Scr, post-procedure
increase in Scr levels from baseline, and urine levels
of KIM-1, NGAL and IL18 after the procedure in the
Dongchongxiacao (Cordyceps) treatment group
were significantly lower than those in the basic
treatment group (P<0.05).
CONCLUSION: Prophylactic treatment with
Dongchongxiacao (Cordyceps) in SAP patients who
undergo coronary angiography or coronary inter-
vention could prevent contrast-induced renal im-
pairment.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
The incidence of contrast-induced nephropathy (CIN)
is increasing owing to the increasing use of contrast me-
dia in percutaneous coronary intervention (PCI). CIN
is an adverse event that results in an increased risk of
morbidity and mortality during hospitalization, pro-
longs hospital stay, increases the incidence of chronic
end-stage renal disease and increases the cost of health-
care.1 No adjunctive medical or mechanical treatment
has been proved to be efficacious in reducing the risk
of CIN.2 There have been few clinical trials to evaluate
the role of Traditional Chinese Medicine (TCM) in the
prevention of CIN.
The objective of the present study was to evaluate the
role of the mushroom Dongchongxiacao (Cordyceps)
for the prophylaxis of CIN in patients with stable angi-
na pectoris (SAP) who underwent coronary angiogra-
phy or coronary intervention.
METHODS
Ethical approval of the study protocol
The study protocol was approved by the Ethics Com-
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mittee of Tianjin Nankai Hospital (Tianjin, China).
All patients provided written informed consent to be
included in this study.
Study population
The present study was conducted at the Department of
Cardiology at Tianjin Nankai Hospital from October
2011 to September 2012. Samples were selected by us-
ing a Random Number Table. One hundred and three
eligible patients with SAP were divided randomly into
two groups: basic treatment (n=51) and Dongchongxi-
acao (Cordyceps) (DCXC) treatment (n=52). Subjects
had to be >18 years and <80 years of age, and SAP had
to conform to guidelines set by the relevant organiza-
tion in China in 2007.3 The exclusion criteria were pa-
tients that were hyperpyrexic or allergic to iodine or
who had: tumors: severe heart failure; severe liver or
kidney failure; disorders of the immune system; blood
diseases.
Intervention
Subjects in the basic treatment group received hydra-
tion, anti-platelet agents, statins, and anticoagulant
therapy. Patients in the DCXC group received corbrin
capsules (Hangzhou Zhongmei Huadong Pharmaceuti-
cals, Hangzhou, China; 3 g; p.o.; t.d.s.) for 3 days be-
fore and after angioplasty. All patients received physio-
logical (0.9%) saline (i.v.) at 1 mL/kg-1·h-1 for 6 h be-
fore, and 12 h after, contrast exposure. An intervention-
al team carried out PCI according to standard practice
using conventional guide catheters, guidewires, balloon
catheters and stents via femoral or radial approaches.
Decisions regarding the procedure were left to the dis-
cretion of the interventional cardiologist. All proce-
dures were undertaken with low-osmolarity non-ionic
contrast media (iopamidol, i.v.). The volume of con-
trast media used was recorded for all patients during
catheterization.
Outcome measures
Serum levels of triglycerides (TG), total cholesterol
(TC), high-density lipoprotein-cholesterol (HDL-C),
low-density lipoprotein-cholesterol (LDL-C), uric acid,
and fibrinogen were assessed at the time of hospital ad-
mission. Serum creatinine (Scr) was assessed at the
time of hospital admission and 1, 2, and 3 days after
the procedure. Values of kidney injury molecule-1
(KIM-1), neutrophil gelatinase-associated lipocalin
(NGAL) and interleukin (IL) 18 in urine were record-
ed before and 1 day after the procedure in patients of
both groups.
Statistical analyses
Continuous variables and categorical variables are the
mean±standard deviation (SD) and percentages, respec-
tively. All samples were tested to ascertain if they fol-
lowed a normal distribution. Comparisons between
groups were undertaken using the Student's t-test for
independent groups. Categorical variables were com-
pared using the χ2 test or the Fisher exact test (if appro-
priate). P<0.05 (two-tailed) were considered signifi-
cant. Statistical analyses were done using SPSS ver 13.0
(SPSS, Chicago, IL, USA).
RESULTS
Baseline clinical and procedural characteristics are list-
ed in Table 1. There was no significant difference be-
tween the two groups with regard to the general condi-
tion for CIN (P>0.05). Overall, CIN occurred in 9 of
103 patients (8.74% ). The prevalence of CIN in the
DCXC treatment group was lower than that in the ba-
sic treatment group (5.77% vs 11.76%) but this differ-
ence was not significant (P>0.05). The mean peak val-
ue of Scr and the increase in Scr level from baseline
(ΔScr) after the procedure in patients in the DCXC
treatment group were significantly lower than those in
the basic treatment group (P<0.05). Within 3 days af-
ter the procedure, all Scr levels were lower in patients
in the DCXC treatment group than those in the basic
treatment group, but only on day 2 was the difference
significant (P<0.05) (Table 2). Within 1 day after the
procedure, all urine levels of KIM-1, NGAL, and IL18
in patients in the DCXC treatment group were lower
than in those in the basic treatment group (P<0.05)
(Table 3).
DISCUSSION
CINisdefinedas a relative increase inScr level fromabase-
line value of ≥25% or an absolute increase of ≥0.5 mg/dL
within 3 days after intravascular administration of con-
trast medium without an alternative etiology.4-6 Howev-
er, the change in Scr level precedes kidney damage and
does not demonstrate losses in renal function in a time-
ly manner. Recent studies have suggested that urine lev-
els of KIM-1, NGAL and IL18 can predict the develop-
ment and progression of CIN.7,8
It is widely recognized that the renal ischemia induced
by hemodynamic change and renal vascular constric-
tion have major roles in the pathogenesis of CIN.9
However, recent studies have shown that oxidative
stress plays an important part in the development and
progression of CIN.10,11 In accordance with these obser-
vations, antioxidants such as N-acetylcysteine and
ascorbic acid have been used in experimental and clini-
cal trials to protect against CIN.12,13 Additional evi-
dence of the effectiveness of an antioxidant strategy
comes from a recent observation with probucol. Probu-
col was shown to attenuate renal damage in patients
who underwent coronary angiography or coronary in-
tervention.14
The renal impairment caused by CIN belongs to the
categories of Bilong, Guange, and Nidu. Contrast me-
dium can be classified into the TCM category of "med-
icine poison, hot and humid, blood stasis". CIN in-
volves the lung, spleen, kidney and other viscera. Triple
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warmer gasification suffocate is the key to pathogenesis
of CIN. The essence of CIN belongs to the scope of de-
ficiency syndrome. The pathogenesis specialty of CIN
is deficiency origin and excess in superficiality.15
Dongchongxiacao (Cordyceps) comprises many amino
acids and inorganic elements. It can increase the toler-
ance of the body to anoxia, promote proliferation of tu-
bular epithelial cells in vitro, and accelerate the repair
of damaged cells.16 Dongchongxiacao (Cordyceps) can
reduce renal vascular resistance, increase renal blood
flow, and elevate the rate of clearance of insulin.17
Dongchongxiacao (Cordyceps) may ameliorate nephro-
toxicity-induced renal dysfunction in rats via antioxi-
dant, anti-apoptotic, and anti-autophagic mecha-
nisms.18 Dongchongxiacao (Cordyceps) can also alleviate
oxidative stress to delay formation of atherosclerotic le-
Characteristic
Age (years)
Men/women
BMI
SBP (mm Hg)
DBP (mm Hg)
HR (beats per minute)
Hypertension [n (%)]
Diabetes mellitus [n (%)]
Stroke [n (%)]
Smoking [n (%)]
DOTP (mL)
VOCM (min)
Cholesterol (mmol/L)
Triglycerides (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
Uric acid (μmol/L)
Fibrinogen (g/L)
LVEF (%)
Dongchongxiacao (Cordyceps) group (n=52)
62.58±3.71
27/25
25.6±4.4
138.5±17.8
70.0±12.3
73.5±10.0
32 (61.54)
22 (42.31)
12 (23.08)
35 (67.31)
246.8±49.7
70.8±8.5
4.8±1.1
1.9±1.4
3.0±0.9
1.2±0.3
340.0±65.7
3.1±0.8
59.3±11.6
Basic treatment group (n=51)
63.9±4.3
28/23
25.0±5.8
141.3±18.2
72.1±10.1
75.3±11.2
28 (54.90)
19 (37.25)
10 (19.61)
32 (62.74)
248.9±48.7
65.9±10.6
4.9±1.10
2.0±1.2
3.0±1.0
1.2±1.2
332.0±70.6
3.0±1.0
61.4±12.0
P value
0.47
0.45
0.68
0.36
0.49
0.41
0.56
0.62
0.73
0.55
0.69
0.71
0.28
0.91
0.41
0.85
0.56
0.41
0.37
Table 1 Baseline clinical and procedural characteristics of study patients
Notes: BMI: body mass index; DBP: diastolic pressure; DOTP: duration of the procedure; HR: heart rate; LVEF: left ventricular ejection
fraction; SBP: systolic pressure; VOCM: volume of contrast medium; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density
lipoprotein-cholesterol.
Characteristic
Baseline Scr (mg/dL)
Day 1 after procedure (mg/dL)
Day 2 after procedure (mg/dL)
Day 3 after procedure (mg/dL)
Peak Scr after procedure (mg/dL)
ΔScr (mg/dL)
Prevalence of CIN [n (%)]
Dongchongxiacao (Cordyceps) group (n=52)
0.98±0.39
1.05±0.38
1.07±0.45
1.06±0.41
1.15±0.47
0.16±0.01
3 (5.77)
Basic treatment group (n=51)
1.06±0.61
1.16±0.65
1.25±0.77
1.15±0.63
1.32±0.75
0.27±0.19
6 (11.76)
P value
0.278
0.192
0.035
0.120
0.044
0.001
0.126
Table 2 Scr levels at baseline and after the procedure in patients from the two groups
Notes: CIN: contrast-induced nephropathy; Scr: serum creatinine.
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sions in rats.19
We used Dongchongxiacao (Cordyceps) to prevent
CIN. CIN occurred in 9 of 103 patients. The preva-
lence of CIN in the DCXC treatment group was lower
compared with that in the basic treatment group. We
selected ΔScr, peak Scr, and urine levels of KIM-1,
NGAL and IL18 after the procedure as an index of re-
nal function. Treatment with Dongchongxiacao (Cordy-
ceps) markedly suppressed the increase in peak values of
Scr and ΔScr. After the procedure, all urine levels of
KIM-1, NGAL and IL18 in patients in the DCXC
group were lower than those in the basic treatment
group. These results strongly suggest the preventative
effect of Dongchongxiacao (Cordyceps) on CIN in SAP
patients exposed to contrast media. Dongchongxiacao
(Cordyceps) can reinforce the kidney, replenish Qi, and
strengthen essence. It can also correct obvious primary
deficiency syndrome.
The present study had a limitation. The study cohort
was small, which would have weakened the statistical
power of the results. The randomized small-scale study
described here showed that prophylactic treatment
with Dongchongxiacao (Cordyceps) in SAP patients
who undergo coronary angiography or coronary inter-
vention could prevent CIN. Further studies are war-
ranted to clarify the preventative effects of
Dongchongxiacao (Cordyceps) on CIN.
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Table 3 Urine levels of KIM-1, NGAL and IL18 at baseline and after the procedure in patients from the two groups
Characteristic
Baseline KIM-1 (ng/mL )
Day 1 after procedure (ng/mL)
Baseline NGAL (ng/mL)
Day 1 after procedure NGAL (ng/mL)
Baseline IL18 (ng/L)
Day 1 after procedure IL-18((ng/L)
Dongchongxiacao (Cordyceps) group (n=52)
0.72±0.06
2.21±0.29
7.98±4.02
39.65±8.42
41.98±4.81
48.10±3.52
Basic treatment group (n=51)
0.69±0.05
5.81±0.32
7.62±3.76
7.36±11.85
40.62±5.85
61.79±4.85
P value
0.365
0.019
0.523
0.001
0.412
0.008
Notes: IL18: interleukin-18; KIM-1: kidney injury molecule-1; NGAL: neutrophil gelatinase-associated lipocalin.
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